Tags

Type your tag names separated by a space and hit enter

Dexlansoprazole for the treatment of esophagitis and GERD.
Drugs Today (Barc). 2010 Feb; 46(2):75-80.DT

Abstract

Occasional acid reflux occurs frequently in the general population but gastroesophageal reflux disease (GERD), a chronic disease that affects millions of adults and children, is diagnosed if persistent reflux occurs more than twice a week. The development of proton pump inhibitors (PPIs) dramatically improved the treatment of GERD; however, the treatment of patients with refractory GERD remains a challenge. Dexlansoprazole (TAK-390MR, Kapidex), a pure enantiomer of lansoprazole, is a PPI that, with a novel dual delayed release formulation, provides prolonged inhibition of gastric acid secretion resulting in marked improvements in symptoms of GERD with high maintenance rates and good tolerability. Dexlansoprazole recently received Food and Drug Administration approval for the once-daily oral treatment of heartburn associated with symptomatic nonerosive GERD, the healing of erosive esophagitis (EE) and the maintenance of healed EE.

Authors+Show Affiliations

University of Worcester, Institute of Science and the Environment, Worcester, UK. s.davies@worc.ac.uk

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20393635

Citation

Davies, Shelley L.. "Dexlansoprazole for the Treatment of Esophagitis and GERD." Drugs of Today (Barcelona, Spain : 1998), vol. 46, no. 2, 2010, pp. 75-80.
Davies SL. Dexlansoprazole for the treatment of esophagitis and GERD. Drugs Today. 2010;46(2):75-80.
Davies, S. L. (2010). Dexlansoprazole for the treatment of esophagitis and GERD. Drugs of Today (Barcelona, Spain : 1998), 46(2), 75-80. https://doi.org/10.1358/dot.2010.46.2.1437714
Davies SL. Dexlansoprazole for the Treatment of Esophagitis and GERD. Drugs Today. 2010;46(2):75-80. PubMed PMID: 20393635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dexlansoprazole for the treatment of esophagitis and GERD. A1 - Davies,Shelley L, PY - 2010/4/16/entrez PY - 2010/4/16/pubmed PY - 2010/7/23/medline SP - 75 EP - 80 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today VL - 46 IS - 2 N2 - Occasional acid reflux occurs frequently in the general population but gastroesophageal reflux disease (GERD), a chronic disease that affects millions of adults and children, is diagnosed if persistent reflux occurs more than twice a week. The development of proton pump inhibitors (PPIs) dramatically improved the treatment of GERD; however, the treatment of patients with refractory GERD remains a challenge. Dexlansoprazole (TAK-390MR, Kapidex), a pure enantiomer of lansoprazole, is a PPI that, with a novel dual delayed release formulation, provides prolonged inhibition of gastric acid secretion resulting in marked improvements in symptoms of GERD with high maintenance rates and good tolerability. Dexlansoprazole recently received Food and Drug Administration approval for the once-daily oral treatment of heartburn associated with symptomatic nonerosive GERD, the healing of erosive esophagitis (EE) and the maintenance of healed EE. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/20393635/Dexlansoprazole_for_the_treatment_of_esophagitis_and_GERD_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1437714 DB - PRIME DP - Unbound Medicine ER -